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Abstract
Background: Nodding syndrome is a poorly understood neurological disorder of unknown aetiology, affecting
several thousand children in Africa. There has been a consistent epidemiological association with infection by the
filarial parasite, Onchocerca volvulus and antibodies to leiomodin and DJ-1, cross-reacting with O.volvulus proteins,
have been reported. We hypothesized that nodding syndrome is a neuro-inflammatory disorder, induced by
antibodies to O.volvulus or its symbiont, Wolbachia, cross-reacting with human neuron proteins and that
doxycycline, which kills Onchocerca through effects on Wolbachia, may be used as treatment.
Methods: This will be a two-arm, double-blind, placebo-controlled, randomised phase II trial of doxycycline 100 mg
daily for six weeks in 230 participants. Participants will be patients’ ages≥8 years with nodding syndrome. They will
receive standard of care supportive treatment. All will be hospitalised for 1–2 weeks during which time baseline
measurements including clinical assessments, EEG, cognitive and laboratory testing will be performed and
antiepileptic drug doses rationalised. Participants will then be randomised to either oral doxycycline (Azudox®,
Kampala Pharmaceutical Industries) 100 mg daily or placebo. Treatment will be initiated in hospital and continued
at home. Participants will be visited at home at 2, 4 and 6 weeks for adherence monitoring. Study outcomes will be
assessed at 6, 12, 18 and 24-month visits. Analysis will be by intention to treat. The primary efficacy outcome
measure will be the proportion of patients testing positive and the levels or titires of antibodies to host neuron
proteins (HNPs) and/or leiomodin at 24 months. Secondary outcome measures will include effect of the
intervention on seizure control, inflammatory markers, cognitive function, disease severity and quality of life.
Discussion: This trial postulates that targeting O.volvulus through drugs which kill Wolbachia can modify the
pathogenic processes in nodding syndrome and improve outcomes. Findings from this study are expected to
substantially improve the understanding and treatment of nodding syndrome.
Trial registration: Registered with clinicaltrials.gov ID: NCT02850913 on 1st August, 2016.
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Background
Nodding syndrome is a complex neurological disorder
of unknown aetiology. The disease burden is unknown
but it is estimated that there are about 10,000 affected
children in eastern and central Africa. Of these, about
3000 live in Northern Uganda [1, 2].
The first reports of nodding syndrome came from
Tanzania in the 1960’s [3]. Subsequent cases were reported
from Liberia [4], South Sudan [5–7] and Uganda [8, 9].
The disease affects previously normally developing chil-
dren characterized by bouts of repetitive head nodding
(the pathognomonic feature). Symptoms develop in chil-
dren between the ages of three and 18 years, and initially,
the head nodding occurs in association with feeding, a
cold breeze or cold weather [7, 10, 11]. Over the years
however, this is complicated by multiple types of seizures,
malnutrition, cognitive and physical decline [1, 7, 10, 12].
There have been many studies of environmental, infec-
tious, toxic and genetic factors to determine aetiology
but the cause remains unknown to date [13–15]. On the
other hand, a consistent epidemiologic association has
been documented between nodding syndrome and infec-
tion with Onchocerca volvulus (a filarial nematode) [6,
10, 12, 13, 15]. This parasite has previously also been as-
sociated with the Nakalanga syndrome (a tropical syn-
drome characterised by short stature and malnutrition)
[16–18]. O.volvulus has in addition been associated with
generalised epilepsy [19]. However, O.volvulus is en-
demic in many parts of Africa, Latin America and Asia
where it causes corneal keratitis (river blindness) but
nodding syndrome has only been reported in parts of
Africa. O. volvulus has also not been observed in brain
tissue. If O. volvulus is involved in the aetiology of nod-
ding syndrome, alternative mechanisms other than dir-
ect parenchymal injury are likely.
We hypothesise that, nodding syndrome is a
neuro-inflammatory disorder, caused by antibodies to an-
tigens from either O.volvulus or its symbiont, Wolbachia,
cross reacting with host neuron proteins (HNPs). Anti-
bodies against HNPs such as the voltage-gated potassium
channel complex (VGKC-complex) including the
leucine-rich glioma inactivated − 1(LGI1) protein and
contactin-associated protein-like-2 (CASPR2), the
N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA), gamma
amino-butyric acid (GABA)A, GABAB and glycine recep-
tors are recognised in severe epileptic disorders [20]. Pre-
ceding infections may play a role, possibly through
molecular mimicry or indirectly by inducing cytokines
and allowing pathogenic antibodies gain access to the
brain (reviewed in [20, 21]). Two pilot studies have specif-
ically demonstrated evidence of possible cross-reacting
antibodies in the pathology of nodding syndrome, includ-
ing to leiomodin and DJ-1 [2, 22].
O.volvulus is transmitted by female blackflies of the
genus Simulium. Infective larvae are injected into the
host during a blood meal. These grow reaching maturity
1–3 years later. The adult worms reside in skin nodules
where they can live for 10–15 years producing millions
of microfilariae. These migrate under the skin and may
be ingested by the next fly to continue the cycle [3].
Ivermectin kills the microfilaria but the adult worm has
no specific drug treatment. However, antibiotic depletion
of Wolbachia, the O.voluvulus symbiotic bacteria, with
tetracyclines such as doxycycline, results in sterilisation
and premature death of the adult worm and marked re-
duction in dermal microfilaria [23]. The outcome of
nodding syndrome could potentially be improved with
such a therapy that kills adult O.volvulus.
This study aims to examine the effects of treating pa-
tients with nodding syndrome, aged 8 years or older,
with oral doses of doxycycline 100mg daily for six weeks
compared to placebo, on serum levels of antibodies to
HNPs (VGKC complex, leiomodin, DJ-1 and others to
be identified in a concurrent case-control study) at 24
months and on seizure control, disease severity, quality
of life, ongoing inflammation and microfilaria density. It
will also assess safety, adherence to treatment and fac-
tors associated with non-adherence.
Methods
Study design
This will be a two-arm double-blind parallel group,
placebo-controlled phase II randomised trial of oral
doxycycline 100 mg daily for six weeks, versus placebo,
for the treatment of nodding syndrome.
Setting
The study will be conducted in the nodding syndrome
affected districts of northern Uganda and will be based
in Kitgum General Hospital. The setup of this trial has
been described elsewhere [24].
Participants
Participants will be children and adolescents with con-
firmed nodding syndrome as defined by the WHO [25] i.e.
A child who has experienced head nodding on two or
more occasions, observed by a trained health worker or
documented on EEG, with symptom onset between the
ages of three and 18 years, plus any one of 1) triggered by
food or cold weather; 2) presence of other seizures or
neurological abnormalities and cognitive decline; 3) clus-
tering in space or time in the local population.
Sample size
From our pilot studies, ~ 50% of patients with prevalent
nodding syndrome had antibodies to a HNPs and ~ 60%
to leiomodin [2, 22]. We hypothesise that among patients
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with new onset nodding syndrome (symptoms < 12
months), six weeks’ therapy with doxycycline will cause a
50% reduction in the proportion of patients with and the
levels or titres of antibodies to HNPs (a reduction from 50
to 25% compared to placebo) at 24months. In Uganda,
however, there has been no incident cases of nodding syn-
drome since 2014. It is anticipated that the intervention
may not be as efficacious in patients with established
symptoms (i.e. patients with symptoms ≥12months) and
the effect on antibodies would be smaller (an anticipated
40% reduction from 50 to 30%). To demonstrate this ef-
fect at 80% power and 5% level of significance and allow-
ing for 10% losses to follow up, we will need to recruit a
total of 230 patients with established symptoms (115 in ei-
ther arm).
Study procedures
Potential participants will be evaluated through a
pre-randomisation phase involving outpatient screening,
obtaining consent and enrolment. Consented partici-
pants will undergo an inpatient assessment phase, a ran-
domisation and treatment initiation phase, an
intervention phase and finally, a follow up and outcome
determination phase, Fig. 1.
Pre-randomisation phase
Potential participants will be identified in specialised
nodding syndrome outpatient clinics or community out-
reach centres. Screening, assent and informed consent
procedures will be performed in the same clinics and the
community outreach centres by study staff. The inclu-
sion criteria will be patients with confirmed nodding
syndrome as defined by the WHO [25] and aged 8 years
or older. Females with a positive urinary HCG (preg-
nancy) test (tested if the participant has experienced me-
narche), those anticipated to migrate away from the
study catchment area, those with known hypersensitivity
to tetracyclines, and those with suspected high likeli-
hood of non-compliance to the study drug or follow-up
schedule will be excluded. Patients on phenobarbitone,
carbamazepine, or phenytoin will first be weaned off and
put on sodium valproate, the standard of care antiepilep-
tic drug, before enrolment.
Inpatient assessment
After eligibility is confirmed and consent obtained, the
subject will be hospitalised for 1–2 weeks in Kitgum Gen-
eral Hospital for baseline assessments. The patients’ treat-
ment will be updated per standard of care protocols. The
clinical assessment will include a review of the pregnancy,
birth and developmental history, the past medical history,
a description of the progressive development of the symp-
toms of nodding syndrome, and the burden and types of
seizures. A detailed physical assessment will also be
performed including a neurologic, psychiatric and cogni-
tive examination. The Gross Motor Function Classifica-
tion System (GMFCS) and the Modified Rankin Scale will
be used to describe gross motor abilities. The
Mini-International Neuropsychiatric Interview for Chil-
dren and Adolescents (MINI-KID) [26] will be used to
document psychiatric disorders and the disorders classi-
fied per the Diagnostic Statistical Manual (DSM)-V cri-
teria; Intellectual Disability will be assessed using the
Child and Adolescent Intellectual Disability Screening
Questionnaire (CAIDS-Q) [27]; nutritional status will be
assessed against WHO 2000 anthropometric standards;
cognitive function will be assessed using the Cogstate - a
computerised cognitive testing program [28], and the
quality of life (QOL) will be assessed using the Quality of
Life in Childhood Epilepsy (QOLCE) questionnaire [29].
All participants not on standard of care treatments will
be initiated on therapy including sodium valproate for sei-
zures, nutritional, physical and psychological therapy as
appropriate. Patients receiving current standard of care
treatment but with ongoing seizures will have their doses
of sodium valproate optimised to 20-35mg/kg/day.
Five-10mls of blood will be drawn for standard of care
testing (full blood count, liver and renal function tests,
and HIV). We will also obtain skin snips for O.volvulus
microfilaria density (on microscopy and Real Time [RT]
PCR) and Wolbachia load testing. Lumbar puncture will
be performed and 3-4mls of cerebrospinal fluid obtained.
Aliquots of plasma, serum and cerebrospinal fluid will
be stored for baseline evaluation of study specific tests.
All will have a 30-min diagnostic electroencephalo-
graphic (EEG) recording. In addition, an overnight EEG
will be obtained in a convenient sample of 45 partici-
pants selected by stratified random sampling to reflect
the five clinical stages of nodding syndrome [30].
Laboratory testing
This will include the microfilaria density, determination of
plasma or serum levels or titres of O.volvulus specific IgG,
and plasma or serum and CSF levels or titres of inflamma-
tory markers. Markers of inflammation will be tested by
ELISA or using Luminex assays. Antibodies to HNPs such
as GAD and the VGKC complex will be tested by radio-
immunoassay and antibodies to LGI-1, CASPR-2, AMPA,
GABAA and GABAB, NMDA and glycine-receptors will
be tested by cell based assays as indicated by
immuno-histology on rodent brain sections [21].
Randomisation, allocation and treatment initiation phase
Once all pre-randomisation assessments are complete, par-
ticipants will be randomised to either doxycycline or pla-
cebo with a 1:1 allocation as per a computer-generated
randomisation schedule stratified by skin snip test results in
to four groups; A, B, C and D. The randomisation code and
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stratification will be prepared by an independent statistician
at a data centre at Global Health Uganda. The study phar-
macy assistant will email the independent data centre with
the study ID and the microscopy results of the skin snip for
O.volvulus and the data centre statistician will allocate the
participant to the study arms.
Eligibility criteria for randomisation are fulfilment of
the enrolment criteria and the dose of sodium valproate
rationalised to at least 20 mg/kg/day (maximum 35mg/
kg/day) if the patient still experiences one or more tonic
clonic seizures a month. Participants reported to be un-
able to swallow capsules, those already enrolled (or who
will enrol) into another trial, and those who withdrew
consent since enrolment, will be excluded from
randomisation.
The intervention drugs (doxycycline capsules [Azudox®]
and placebo) will be obtained from Kampala Pharmaceut-
ical Industries, Uganda. The active drug and the placebo
will be labelled with the study code by Kampala Pharma-
ceutical Industries in collaboration with the independent
Fig. 1 Study design, flow and participant follow up and assessments. Figure is a schematic diagram that shows a time schedule of enrolment,
interventions, assessments, and visits for participants
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statistician. Each Azudox capsule contains doxycycline
hyclate equivalent to 100mg of doxycycline base. In the
treatment of Onchocerca volvulus, doxycycline is given in
doses of 100-200mg/day for 4–6 weeks [31]. We chose
the lower dose of 100mg/day since most participants will
be adolescents many of who will also have wasting. With
an average weight of 33 kg, we anticipate this dose will
translate to ~ 3mg/kg/day. The two interventions will be
identical in the number of capsules (one) per day and tim-
ing. The drug administration procedures will also be iden-
tical. Both the caretakers and investigators will be blinded.
However, in the event of medical emergency un-blinding
of an individual participant to the PI or safety monitoring
teams may be conducted. Otherwise, all treatment alloca-
tions will only be disclosed after the data is locked and a
statistical analysis plan is in place.
Administration of the trial medication
The intervention drugs will be packaged in capped plas-
tic containers each containing 50 capsules (42 + 8 extra
capsules). Treatment will be initiated in hospital and
continued at home. The first dose will be administered
under direct observation at the clinic. Participants and
their caretakers will then be carefully instructed about
taking subsequent doses before they return home. Each
participant will be visited at home at 2, 4 and 6 weeks
for adherence and safety monitoring (detailed below).
Parents/carers will be reminded weekly through mobile
phone contact to ensure the participants take the
assigned interventions.
The product will be taken with water between 6.00–
9.00 am and at about the same time each day. Should a
carer forget to give the dose at the set time, they will be
advised to give it as soon as this is realised and to con-
tinue the recommended regimen until the dose is com-
pleted. Participants will be observed for at least 30 min
after taking the medication. Should they vomit within
30min of receiving the intervention drug, the full dose
will be re-administered. Such vomiting will be docu-
mented. On a single day, repeat dosing will be attempted
once. The eight additional capsules in each pack are to
cater for such eventualities.
Intervention phase, adherence and safety monitoring
To minimise losses to follow up and aid follow up visits
in the home, a contact cell phone number will be re-
corded prior to discharge and the participants be accom-
panied home by a home visitor who will also draw a
sketch map to document the route home and obtain the
Global Positioning Satellite (GPS) data of the home.
During each visit, the home visitor will document ad-
verse events, ensure seizures are documented in a seiz-
ure diary, conduct pill counts and counsel on adherence.
Participants with < 80% adherence at weeks 2 and 4 will
be visited again the following week and have additional
counselling. Intake of the study drug on the day of the
home visit will be directly observed. Participants will
continue to attend the 1–2 monthly non-study clinical
visits.
Adverse events (AEs) and serious adverse events
(SAEs) will be documented following ICH GCP princi-
ples and all SAEs reported to the DSMB and ethics com-
mittees. If children are found to be ill during these
home-visits they will be referred to the study clinic for
further evaluation as part of the unscheduled visits.
Follow period and study outcome determination
Study participants will be re-evaluated at 6, 12, 18 and
24months. Only clinical assessments will be performed
at 6, 12 and 18 months. At 24 months, however, partici-
pants will again be hospitalised for one week for in-
patient observation and testing, during which all the
pre-randomisation procedures and tests will be repeated
to determine study outcomes.
Unscheduled visit (passive follow-up)
Parents will be instructed to bring the participants to
the study clinic for any suspected illness. The ‘chief com-
plaint’ and ‘diagnoses’ will be recorded using a standard
list based on the International Classification of Disease
(ICD-10) for children. Consent will be sought from par-
ents or guardians of participants who die for a formal
post mortem or verbal autopsy if the post-mortem is not
possible.
Concomitant drugs
All concomitant medications taken during the study will
be recorded with the indication, dose information, and
dates of administration. However, concomitant use of
any other tetracycline is prohibited during the 24-month
study period. If needed, a macrolide antibiotic will be
used. Randomised participants who take prohibited
medications will cease participation. Such participants
will remain in the trial and will be included in the pri-
mary, intention-to-treat analysis, but excluded from the
per-protocol analysis. Doxycycline interacts with barbi-
turates (e.g. phenobarbitone), carbamazepine, cimetidine,
hydantoins (e.g. phenytoin), and rifampicin. These drugs
decrease the effectiveness of doxycycline and so will not
be co-administered. Those requiring rifampicin will
cease participation. On the other hand, side effects of
other drugs such as digoxin, insulin, methotrexate, war-
farin, or theophylline may be accentuated. Patients re-
quiring these medications will be excluded. Doxycycline
may also decrease the effectiveness of penicillin. Thus,
during the six-week study drug administration period,
alternative antibiotics (co-trimoxazole and cephalospo-
rins) will be used if indicated.
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Data collection and management
Data collection
Data will majorly be quantitative and will be obtained
from clinical observations, interviews, patient maintained
logs, neurophysiologic and cognitive testing, brain imaging
and testing of tissue samples. Data will be collected and
recorded at the point of contact at the health facility or
the participants’ home. Cognitive function on the Cog-
State is exclusively electronic and no additional entry re-
quired. Follow up data obtained during home visits will
also be collected electronically but all the other data will
be paper based. Data forms will be checked at the end of
each day for completeness and accuracy.
Data management
Prior to the start of the study, we will develop standard
operating procedures for all documentation. Study
personnel will undergo training in procedures and docu-
mentation. Updates of this training will again be pro-
vided in the second and third years. Paper based data
will be double entered into the databases with validation
limits. Once data entry and cleaning are completed, any
hard copies of case record forms will be stored for a
minimum 7 years as per local guidelines.
Study monitoring and data quality control
Internal monitoring of the study will be performed by
Makerere University Clinical Trials Unit in collaboration
with the Amsterdam Institute for Global Health and ex-
ternal monitoring by the East African Consortium for
Clinical Research Monitors. In each case, at least five
quality audits are provided for.
Assessment of efficacy and safety
Primary efficacy outcome
The objective of the trial is to determine if targeting
O.volvulus through drugs which kill Wolbachia can
modify the pathogenic processes in nodding syndrome.
We will therefore investigate the effects of doxycycline
compared to placebo on the presence and titres of
serum antibodies to HNPs (identified in the concurrent
case-control study) or leiomodin and on inflammatory
markers, the microfilaria density and Wolbachia load.
The primary efficacy measure will be the proportion pa-
tients testing positive for and levels or titres of anti-
bodies to HNPs or leiomodin at 24 months.
Secondary efficacy outcomes
Key secondary efficacy measures at 24months will include:
1. Mean change in serum levels or titres of antibodies
to HNPs or leiomodin and serum levels or titres of
inflammatory markers.
2. Mean change in dermal microfilaria density on real
time PCR at 24 months.
3. The proportions of patients achieving seizure
freedom (≥1 month without head nodding or
convulsive seizures), mean change in Cogstate
scores, the proportions of patients with inter ictal
epileptiform discharges on diagnostic EEG,
proportion of participants with Gross Motor
Function Classification System (GMFCS) scores 3–
5; and the proportion of participants with mental
health disorders on the MINI-KID and intellectual
disability on the CAIDS-Q and the proportion of
participants with improved Quality of Life.
4. Others will be mean changes in weight-for-age,
height-for-age (stunting), and height-for-weight
(wasting) Z-scores and proportions of participants
with wasting and stunting (Z-scores <− 3 SD)
5. Incidence rate of non-nodding syndrome sick clinic
visits and all cause sick clinic visits; incidence rate of
all-cause hospital admissions and all-cause mortality
Secondary safety outcomes
Secondary safety outcome measures will be the inci-
dence rate of serious adverse events and adverse events
up to 24months after enrolment.
Statistical analysis
Analysis will be by intention to treat. The analysis will
compare the proportions of patients testing positive for
and the levels or titres of antibodies to HNPs or leiomodin
at baseline and at 24months in both arms. Both crude
(unadjusted) and adjusted effect estimates will be com-
puted. The chi square test will be used to compare pro-
portions of children with the different antibodies in the
two arms; the Students t-test will be used for means of
normally distributed data and the Mann-Whitney U test
for skewed data. We will also determine the mean change
or reduction in the levels or titres of the antibodies and in-
flammatory markers with the intervention. Time to event
(e.g. to seizure resolution) will be measured from the date
of randomisation using Kaplan Meyer Survival analysis
and by Cox regression analysis. For the cognitive tests, in
addition to classification as impaired or not (in compari-
son to norms determined from unaffected sibling controls
in the concurrent case control study), we will also meas-
ure mean improvements in scores. The rates determined
will be adjusted for age, HIV infection, weight for height z
scores and corrected for multiple testing. We will examine
safety (serious adverse events and adverse events) and as-
sess compliance and the factors for poor compliance.
Interim analyses and criteria for termination of the trial
An interim analysis is planned for when a total of 132
participants have completed the 24-month assessment.
Idro et al. BMC Neurology           (2019) 19:35 Page 6 of 9
This number will be sufficient to demonstrate a 50% re-
duction in the proportion of participants testing positive
for antibodies to HNPs at 24 months compared to base-
line at β = 0.80 and α = 0.05. This information will be
reviewed by an independent Data and Safety Monitoring
Committee (composed of an experienced epidemiologist
who will chair the committee, a paediatric neurologist
and a general paediatrician) which may recommend
stopping the trial on safety rules or efficacy reasons. The
Peto-Haybittle rule will be used to stop the trial for effi-
cacy reasons: i.e. to consider stopping the trial early be-
cause of efficacy, a p-value < 0.001 should be achieved at
the interim analysis. Accordingly, the early stopping
rules will be: (1) proof beyond reasonable doubt of a dif-
ference in primary outcome between the study and con-
trol groups and (2) evidence that would substantially
alter the choice of treatment for patients. Otherwise, the
overall significance level of the final analysis will be p <
0.05. However, in order not to miss an early but clinically
relevant improvement in secondary outcomes and in par-
ticular, seizure control, Makerere University School of
Medicine Research and Ethics Committee recommended
that the first interim analysis should be conducted when
132 participants complete the 12-month assessment. If
significant differences fulfilling the Peto-Haybittle rule
are observed at this stage, the trial may be stopped.
Discussion
The goal of this study is to understand the pathogenesis
of, and to develop specific interventions for, nodding syn-
drome. Currently, there is no specific treatment for nod-
ding syndrome. The only available treatment is a package
of therapies aimed at symptomatic relief [32]. This project
has the potential to advance the understanding of nodding
syndrome, allow definitive diagnosis and gain insight into
potential new approaches for treatment and prevention. If
evidence of neuro-inflammation is found and/or specific
autoantibodies, immune-modulatory therapies, for ex-
ample with high dose steroids, may be considered at
symptom-onset [2]. In addition, a biologic association
between nodding syndrome and O.volvulus would allow
escalation of treatments and prevention. If a potential use
for doxycycline, as treatment for nodding syndrome is ob-
served, it would also be a proof of principle that treatment
is possible in older children. Such a strategy could also be
explored for younger newly affected children. It is import-
ant to point out that the proposed use of doxycycline is
based on its effectiveness as treatment for adult O. volvu-
lus. Its success will not depend on Wolbachia playing a
direct role in the pathogenesis of NS (although it may), ra-
ther, it is a test of the broader hypothesis that O.volvulus
plays a role in the pathogenesis of NS.
The approach of using doxycycline is supported by the
facts that (1) O.volvulus infection has had the most
consistent association with nodding syndrome out of
many potential risk factors examined to date [33]; (2)
doxycycline is a cheap and safe drug and the only cura-
tive treatment for adult O.volvulus currently available
[23]; (3) a direct intervention has considerable advan-
tages over epidemiological association studies in eluci-
dating causality. This is thus a low risk but potentially
high gain approach: a positive result would have great
significance in understanding both pathogenesis and of-
fering a hope of treatment, whilst a negative result
would still be helpful in indicating that whatever the
pathogenesis, a simple approach to reducing O.volvulus
load may not necessarily offer an advantage.
The trial has as one of its major strengths - the dual
benefit of potentially determining both the pathogenesis
of nodding syndrome and providing a specific treatment
intervention. This is supported by the use of both clinical
and laboratory biomarkers either as primary or secondary
outcome measures. The main weakness is that with the
decline in incident cases who would potentially register
most improvements with treatment, the study will have to
rely on patients with established symptoms in whom,
probably lower degrees of improvements will be observed.
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